PTC Therapeutics
PTCT
141 hedge funds and large institutions have $1.17B invested in PTC Therapeutics in 2015 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 58 increasing their positions, 45 reducing their positions, and 40 closing their positions.
33% more capital invested
Capital invested by funds: $880M → $1.17B (+$294M)
29% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 45
0% more call options, than puts
Call options by funds: $46M | Put options by funds: $45.8M
10% less funds holding
Funds holding: 157 → 141 (-16)
38% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 40
Top Buyers
Top Sellers
PTCT Hedge Fund Activity: Q4 2015 in Review
141 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2015, worth a combined $1.17B — up 33% from $880M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of PTCT and 25 opened new positions — a net loss of 15 holders — while 45 trimmed existing stakes and 58 added.
The largest buyer was Wellington Management Group, adding an estimated $35.3M. The largest seller was Bain Capital Public Equity Management, exiting entirely with an estimated $24.2M sold.
- 141 institutional investors held PTC Therapeutics (PTCT) as of Q4 2015, down from 157 in Q3 2015.
- Funds reported $1.17B of PTC Therapeutics stock for Q4 2015, up 33% quarter-over-quarter.
- 25 funds opened new PTC Therapeutics positions in Q4 2015 and 40 closed out, a net change of -15 holders.
- The largest PTC Therapeutics buyer in Q4 2015 was Wellington Management Group, an estimated $35.3M added.
- The largest PTC Therapeutics seller in Q4 2015 was Bain Capital Public Equity Management, an estimated $24.2M sold.
Based on aggregated 13F filings for Q4 2015.